O Brien Greene & Co. Inc Acquires 73 Shares of Amgen Inc. (NASDAQ:AMGN)

O Brien Greene & Co. Inc raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 0.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,377 shares of the medical research company’s stock after purchasing an additional 73 shares during the quarter. Amgen accounts for approximately 2.7% of O Brien Greene & Co. Inc’s investment portfolio, making the stock its 13th largest holding. O Brien Greene & Co. Inc’s holdings in Amgen were worth $8,178,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in AMGN. Morningstar Investment Management LLC increased its position in shares of Amgen by 9.6% during the fourth quarter. Morningstar Investment Management LLC now owns 2,729 shares of the medical research company’s stock worth $711,000 after acquiring an additional 239 shares during the period. Hussman Strategic Advisors Inc. increased its stake in shares of Amgen by 40.0% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 14,700 shares of the medical research company’s stock valued at $3,831,000 after buying an additional 4,200 shares during the period. Zullo Investment Group Inc. lifted its stake in Amgen by 2.8% in the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after acquiring an additional 37 shares during the period. Advyzon Investment Management LLC purchased a new position in Amgen during the 4th quarter valued at about $232,000. Finally, WealthBridge Capital Management LLC lifted its position in shares of Amgen by 4.7% in the 4th quarter. WealthBridge Capital Management LLC now owns 1,073 shares of the medical research company’s stock worth $280,000 after purchasing an additional 48 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. This trade represents a 16.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the sale, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 35,405 shares of company stock worth $10,410,596 in the last ninety days. Company insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the subject of several recent research reports. Redburn Partners reduced their price target on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. StockNews.com downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Wells Fargo & Company lowered their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. Citigroup reduced their target price on Amgen from $310.00 to $295.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial lowered their price target on Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $314.09.

Amgen Stock Up 0.5 %

Shares of AMGN stock opened at $294.27 on Thursday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $158.18 billion, a P/E ratio of 38.98, a P/E/G ratio of 2.53 and a beta of 0.56. The stock has a 50 day moving average of $275.15 and a 200 day moving average of $300.77. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, sell-side analysts expect that Amgen Inc. will post 20.6 EPS for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.24%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.